{"analyses":[{"ciLowerLimit":".91","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.54","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValueComment":"Two-sided. Not adjusted for multiple comparisons. A-priori threshold for significance 0.05.","paramType":"Hazard Ratio (HR)","paramValue":"1.18","statisticalMethod":"Poisson regression"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"3.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34304"},{"groupId":"OG001","value":"34253"}],"units":"Participants"}],"description":"Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.","groups":[{"description":"Participants receive standard medical care.","id":"OG000","title":"Control"},{"description":"Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years.","id":"OG001","title":"Ovarian Screening"}],"paramType":"NUMBER","populationDescription":"Female participants, excluding females without ovaries at baseline, were analyzed. An intention-to-treat analysis was performed.","reportingStatus":"POSTED","timeFrame":"Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.","title":"Ovarian Cancer Death Rates (Including Primary Peritoneal and Fallopian Tube Cancers)","type":"PRIMARY","unitOfMeasure":"Deaths per 10,000 PY"}